{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 14,
  "pageCount": 27,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Includes a highlighted section emphasizing the 10 million women actively seeking treatment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/14",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.288,
        "w": 0.193,
        "x": 0.628,
        "y": 0.312
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0e47eb9-4dfb-421c-90e7-8580d3b232dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.08,
        "y": 0.315
      },
      "kind": "list",
      "text": "33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal.1,2\n10 million women (~50% of the US women aged 21-60 who experience symptoms of low or no sexual arousal) are considered distressed and actively seeking treatment.1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aa13711-eac4-4221-a94a-6b2e7d5bce2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC.\n2. Based on US Census projections for 2016.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09cdf686-fb4a-40cc-9ee7-1b67d329faee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "title",
      "text": "FSAD – What is the incidence?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88b3cb59-e782-4089-9412-c5e7e6333492",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "1cf04a2f-e9b6-416b-b215-356cb28b9845",
      "evidence": "The slide provides market sizing information for FSAD, indicating a focus on a specific segment of the population.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 14,
      "beatId": "cb1e3474-b2aa-4538-9235-0a8a68ce1eb6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 14-15 highlight the incidence of FSAD and the market opportunity for a pharmacologic treatment",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "946bdaf4-2f0d-4bd9-b675-a10399e70a25",
      "evidence": "The deck implies that not treating FSAD has significant consequences, but does not explicitly state the cost of inaction",
      "position": 0,
      "objective": "What is the cost of not treating FSAD?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}